68Ga-citrate PET/MR Imaging for Glioma

Susan Chang

Status

Terminated

Conditions

Glioma

Treatments

Drug: 68Ga-citrate PET/MR

Study type

Observational

Funder types

Other

Identifiers

NCT03335280

181016

NCI-2020-00335 (Registry Identifier)

Details and patient eligibility

About

This is a prospective, single center, open-label study in adult patients with presumed World Health Organization (WHO) grade 3 or 4 glioma who will be undergoing surgical resection as standard of care. In some cases, patients will have had biopsy. Study participants will undergo 68Ga-citrate Positron Emission Tomography / magnetic resonance (PET/MR) prior to surgery.

Enrollment

2 patients

Sex

All

Ages

18 to 85 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

World Health Organization (WHO) grade 3 or 4 glioma planning to undergo surgery
Age >= 18 yrs.
Karnofsky performance status of >= 60
Ability to understand a written informed consent document, and the willingness to sign it.

Cohort A:

Positive for Phosphatase and Tensin Homolog (PTEN) deletion, confirmed by immunohistochemistry of tissue biopsy

Cohort B:

Negative for PTEN deletion, confirmed by immunohistochemistry of tissue biopsy

Exclusion criteria

Contraindications to Positron Emission Tomography (PET) imaging (e.g. pregnant or breast-feeding woman)
Contraindications to magnetic resonance (MR) imaging (e.g. pacemakers, metallic implants, etc.)